CIAM
ESPR

Caitong International Asset Management’s Esperion Therapeutics ESPR Stock Holding History

Caitong International Asset Management’s Portfolio ESPR Stock Details ESPR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$107 Sell
39
-36,705
-100% -$116K ﹤0.01% 1958
2025
Q4 		$136K Buy
36,744
+5,492
+18% +$17.7K 0.03% 315
2025
Q3 		$82.8K Buy
31,252
+31,175
+40,487% +$60.3K 0.06% 206
2025
Q2 		$76 Sell
77
-2,795
-97% -$2.8K ﹤0.01% 1854
2025
Q1 		$4.14K Sell
2,872
-2,566
-47% -$4.73K ﹤0.01% 1077
2024
Q4 		$12K Buy
+5,438
New +$12.7K 0.01% 918

Other funds holding ESPR

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
WA
Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return
TSC
Two Seas Capital Rye, New York $7.15B AUM 169.27% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Caitong International Asset Management's ESPR Position: Q1 2026 in Review

Caitong International Asset Management reduced its Esperion Therapeutics (ESPR) stake by 100% in Q1 2026, selling an estimated $116K and leaving 39 shares worth $107. The position accounts for ﹤0.01% of the portfolio, ranked #1958.

Caitong International Asset Management first reported a position in ESPR in Q4 2024 and has held it in 6 quarters since. The position peaked at $136K in Q4 2025. 205 funds tracked by Wall St. Rank hold ESPR as of Q1 2026.

  • Caitong International Asset Management held 39 shares of Esperion Therapeutics worth $107 as of Q1 2026.
  • Caitong International Asset Management sold 36,705 Esperion Therapeutics shares in Q1 2026, an estimated $116K.
  • Esperion Therapeutics made up ﹤0.01% of Caitong International Asset Management's portfolio in Q1 2026, its #1958 holding.
  • Caitong International Asset Management first reported a position in Esperion Therapeutics in Q4 2024 and has held it in 6 quarters since.
  • Caitong International Asset Management's Esperion Therapeutics position peaked at $136K in Q4 2025.
  • 205 funds tracked by Wall St. Rank held Esperion Therapeutics as of Q1 2026.

Based on Caitong International Asset Management's 13F filing for Q1 2026, filed 11 May 2026.